Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer

Maurie Markman, MD


August 22, 2022

Liquid biopsy, also known as ctDNA, is emerging as a complementary technique to NGS. Liquid biopsy is being explored to screen for cancers, diagnose cancers, monitor for progression or relapse, and direct therapy selection. Studies have shown that liquid biopsy, with a broader view of systemic tumor evolution, can yield valuable information for certain tumor types that might be missed with localized tissue biopsy. Recent advances in NGS technology enable comprehensive genomic profiling combined with the sensitivity and specificity required for liquid biopsy applications.

Learn more about liquid biopsy with NGS technology.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.